Discovery of Innovative Therapeutics: Today’s Realities and Tomorrow’s Vision. 2. Pharma’s Challenges and Their Commitment to Innovation

The pharmaceutical industry is facing enormous challenges, including reduced efficiency, stagnant success rate, patent expirations for key drugs, fierce price competition from generics, high regulatory hurdles, and the industry’s perceived tarnished image. Pharma has responded by embarking on a rang...

Full description

Saved in:
Bibliographic Details
Published in:Journal of medicinal chemistry 2014-07, Vol.57 (13), p.5525-5553
Main Authors: Abou-Gharbia, Magid, Childers, Wayne E
Format: Article
Language:English
Subjects:
Biopharmaceutics
Clinical Trials as Topic
Drug Discovery - methods
Drug Industry - economics
Drug Industry - trends
Drugs, Generic
Efficiency
Humans
Inventions
Outsourced Services - economics
Outsourced Services - standards
Patents as Topic
Research - economics
Translational Medical Research
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The pharmaceutical industry is facing enormous challenges, including reduced efficiency, stagnant success rate, patent expirations for key drugs, fierce price competition from generics, high regulatory hurdles, and the industry’s perceived tarnished image. Pharma has responded by embarking on a range of initiatives. Other sectors, including NIH, have also responded. Academic drug discovery groups have appeared to support the transition of innovative academic discoveries and ideas into attractive drug discovery opportunities. Part 1 of this two-part series discussed the criticisms that have been leveled at the pharmaceutical industry over the past 3 decades and summarized the supporting data for and against these criticisms. This second installment will focus on the current challenges facing the pharmaceutical industry and Pharma’s responses, focusing on the industry’s changing perspective and new business models for coping with the loss of talent and declining clinical pipelines as well as presenting some examples of recent drug discovery successes.
ISSN:0022-2623
1520-4804
DOI:10.1021/jm401564r